A recent study from the Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland shows that “GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer.” This study was published in the 29 July 2014 issue of the Journal “Cell Metabolism” (the no.1 journal in Metabolism; and I.F: 16.747) by Prof. Etienne Meylan, Masin M and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin-based anti-metastasis therapy: Interleukin-1β (IL-1β) inhibits epithelial-mesenchymal transition and cancer cell proliferation via down regulation of GLUT3.
Significance: The study presented here suggests, for the first time, that IL-1β, by increasing the expression of its target gene, it may decrease the expression of GLUT3. Thereby, it may inhibit glycolysis. Thus, pharmacological formulations encompassing ” IL-1β activators” may be used to stall the progression of invasive human tumors.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Interleukin-based anti-metastasis therapy: Interleukin-1β (IL-1β) inhibits epithelial-mesenchymal transition and cancer cell proliferation via down regulation of GLUT3, 23/March/2015, 12.48 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
Undisclosed information: How Interleukin-1β (IL-1β) suppresses the expression of GLUT3
* Research cooperation